Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
Department of Radiology, University of Naples Parthenope and SDN Istituto Ricerca Diagnostica Nucleare, Naples, Italy.
J Nucl Med. 2015 Mar;56(3):436-43. doi: 10.2967/jnumed.114.145011. Epub 2015 Jan 29.
MR imaging and (18)F-FDG PET/CT play central and complementary roles in the care of patients with gynecologic cancer. Because treatment often requires combinations of surgery, radiotherapy, and chemotherapy, imaging is central to triage and to determining prognosis. This article reviews the use of the 2 imaging modalities in the initial evaluation of 3 common cancers: uterine cervical, uterine endometrial, and epithelial ovarian. Imaging features that affect management are highlighted, as well as the relative strengths and weaknesses of the 2 modalities. Use of imaging after initial therapy to assess for recurrence and to plan salvage therapy is described. Newer functional and molecular techniques in MR imaging and PET are evaluated. Finally, we describe our initial experience with PET/MR imaging, an emerging technology that may prove to be a mainstay in personalized gynecologic cancer care.
磁共振成像（MR）和（18）F-氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描（PET/CT）在妇科癌症患者的治疗中发挥着核心和互补作用。由于治疗通常需要手术、放疗和化疗相结合，影像学对于分诊和判断预后至关重要。本文综述了这两种成像方式在三种常见癌症（子宫颈癌、子宫内膜癌和上皮性卵巢癌）初始评估中的应用。重点介绍了影响治疗管理的影像学特征，以及这两种方式各自的相对优势和劣势。还描述了初始治疗后利用影像学评估复发情况和规划挽救治疗的方法。对MR成像和PET中更新的功能及分子技术进行了评估。最后，我们介绍了我们在PET/MR成像方面的初步经验，这是一项新兴技术，可能会成为个性化妇科癌症治疗的支柱。
